drugset
drugset / Trial / NCT07254585

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

NCT07254585 ↗

Phase 2 Recruiting 70 enrolled CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.

Timeline

Start
2025-12-18
Primary completion
2026-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SYS6010 Monoclonal antibody — —
Background Enlonstobart Monoclonal antibody — —

Indications

head and neck squamous cell carcinoma